Aurobindo Expects Sandoz Business To Over-Perform

Aurobindo is betting that its $1bn purchase of Sandoz’ US assets will beat its earlier expectations and help to fuel significant growth for the Indian firm. It expects the acquisition, the company’s biggest ever, to close within 8-12 weeks.

Rocket
Aurobindo Believes The Sandoz Business Will Exceed Previous Expectations • Source: Shutterstock

Aurobindo Pharma said it expects to close its big-ticket purchase of Sandoz’ US dermatology business and general oral solids portfolio within eight to 12 weeks as it reported an 11% jump in quarterly profit to INR5.85bn ($84.3m) from a year earlier.

The Indian firm added that the Sandoz acquisition, which plugs key product gaps and includes three manufacturing plants, may give...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business